In Brief: AccuMed/Olympus
This article was originally published in The Gray Sheet
Executive Summary
AccuMed/Olympus: AccuMed ships the first 25 AcCell 2000 and 2001 automated cytopathology systems to Olympus, fulfilling initial shipment requirements under a recent distribution agreement. The agreement gives Olympus exclusive rights in the Western Hemisphere to distribute AccuMed's AcCell workstations, which are used in screening Pap smear and other cell samples. The deal also includes rights to the yet-to-be-approved AccuMap system, which employs software to "map and automatically focus the cell specimen prior to human screening," AccuMed says. AccuMed plans to begin training Olympus' technical and quality personnel during the week of July 8. In cooperation with Olympus, AccuMed can continue to promote the system in the Americas...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.